{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:01:30Z","timestamp":1780509690876,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06718"],"award-info":[{"award-number":["22K06718"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00280-022-04479-3","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T16:02:54Z","timestamp":1664553774000},"page":"421-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review"],"prefix":"10.1007","volume":"90","author":[{"given":"Takuya","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-0063","authenticated-orcid":false,"given":"Kosuke","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"4479_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F (2020) Gastric cancer. Lancet 396:635\u2013648. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5","journal-title":"Lancet"},{"key":"4479_CR2","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O\u2019Bryant C, Chow LQ, Serkova NJ, Meropol NJ (2010) Phase I pharmacologic and biologic study of Ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780\u2013787. https:\/\/doi.org\/10.1200\/JCO.2009.23.7537","journal-title":"J Clin Oncol"},{"key":"4479_CR3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:846\u2013856. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0040","journal-title":"Cancer Immunol Res"},{"key":"4479_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","volume":"9","author":"L Liu","year":"2018","unstructured":"Liu L (2018) Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 9:15\u201332. https:\/\/doi.org\/10.1007\/s13238-017-0408-4","journal-title":"Protein Cell"},{"key":"4479_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s10120-001-8012-x","volume":"4","author":"M Tahara","year":"2001","unstructured":"Tahara M, Ohtsu A, Boku N, Nagashima F, Muto M, Sano Y, Yoshida M, Mera K, Hironaka S, Tajiri H, Yoshida S (2001) Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer 4:212\u2013218. https:\/\/doi.org\/10.1007\/s10120-001-8012-x","journal-title":"Gastric Cancer"},{"key":"4479_CR6","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3748\/wjg.v12.i9.1412","volume":"12","author":"M Kobayashi","year":"2006","unstructured":"Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K (2006) Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 12:1412\u20131415. https:\/\/doi.org\/10.3748\/wjg.v12.i9.1412","journal-title":"World J Gastroenterol"},{"key":"4479_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00280-012-2066-9","volume":"71","author":"H Tamegai","year":"2013","unstructured":"Tamegai H, Kaiga T, Kochi M, Fujii M, Kanamori N, Mihara Y, Funada T, Shimizu H, Jinno D, Takayama T (2013) Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites. Cancer Chemother Pharmacol 71:727\u2013731. https:\/\/doi.org\/10.1007\/s00280-012-2066-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"4479_CR8","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s00134-004-2428-9","volume":"30","author":"R Mehrotra","year":"2004","unstructured":"Mehrotra R, De Gaudio R, Palazzo M (2004) Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 30:2145\u20132156. https:\/\/doi.org\/10.1007\/s00134-004-2428-9","journal-title":"Intensive Care Med"},{"key":"4479_CR9","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1592\/phco.20.15.1204.34586","volume":"20","author":"BJ Delauter","year":"2000","unstructured":"Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zuhowski EG, Plunkett W, Zamboni WC (2000) Pharmacokinetics of gemcitabine and 2\u2032,2\u2032-difluorodeoxyuridine in a patient with ascites. Pharmacotherapy 20:1204\u20131207. https:\/\/doi.org\/10.1592\/phco.20.15.1204.34586","journal-title":"Pharmacotherapy"},{"key":"4479_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/FTD.0000000000000926","volume":"43","author":"T Kaneko","year":"2021","unstructured":"Kaneko T, Doki K, Yamada T, Niisato Y, Homma M (2021) Bevacizumab distribution into ascitic fluid decreases serum drug exposure: a case of metastatic colon cancer. Ther Drug Monit 43:813\u2013814. https:\/\/doi.org\/10.1097\/FTD.0000000000000926","journal-title":"Ther Drug Monit"},{"key":"4479_CR11","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00277-012-1410-9","volume":"91","author":"Y Hiroshima","year":"2012","unstructured":"Hiroshima Y, Tajima K, Shiono Y, Suzuki I, Kouno K, Yamamoto M, Kato Y, Kato T (2012) Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites. Ann Hematol 91:1499\u20131500. https:\/\/doi.org\/10.1007\/s00277-012-1410-9","journal-title":"Ann Hematol"},{"key":"4479_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2169\/internalmedicine.55.5987","volume":"55","author":"T Shima","year":"2016","unstructured":"Shima T, Kamezaki K, Higashioka K, Takashima S, Yoshimoto G, Kato K, Muta T, Takenaka K, Iwasaki H, Miyamoto T, Akashi K (2016) Ascites retention during Mogamulizumab treatment in a patient with adult T-cell leukemia\/lymphoma. Intern Med 55:1793\u20131796. https:\/\/doi.org\/10.2169\/internalmedicine.55.5987","journal-title":"Intern Med"},{"key":"4479_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0009-9236(98)90024-8","volume":"64","author":"J Kovarik","year":"1998","unstructured":"Kovarik J, Breidenbach T, Gerbeau C, Korn A, Schmidt A-G, Nashan B (1998) Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 64:66\u201372. https:\/\/doi.org\/10.1016\/S0009-9236(98)90024-8","journal-title":"Clin Pharmacol Ther"},{"key":"4479_CR14","unstructured":"European medicines agency (EMA) (2022) Cyramza-epar product information. Available at http:\/\/www.ema.europa.eu. Accessed 16 Jan 2022."},{"key":"4479_CR15","unstructured":"European medicines agency (EMA) (2022) Opdivo-epar scientific discussion. Available at http:\/\/www.ema.europa.eu. Accessed 16 Jan 2022."},{"key":"4479_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2012","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A (2012) Malignant ascites: pathophysiology and treatment. Int J Clin Oncol 18:1\u20139. https:\/\/doi.org\/10.1007\/s10147-012-0396-6","journal-title":"Int J Clin Oncol"},{"key":"4479_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s10147-020-01810-x","volume":"26","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Yamada T, Sugaya A, Ueyama S, Yamamoto Y, Moriwaki T, Hyodo I (2021) Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden. Int J Clin Oncol 26:370\u2013377. https:\/\/doi.org\/10.1007\/s10147-020-01810-x","journal-title":"Int J Clin Oncol"},{"key":"4479_CR18","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1097\/00007611-200295100-00010","volume":"95","author":"B Yildirim","year":"2002","unstructured":"Yildirim B, Sezgin N, Sari R, Sevinc A, Hilmioglu F (2002) Complement and immunoglobulin levels in serum and ascitic fluid of patients with spontaneous bacterial peritonitis, malignant ascites, and tuberculous peritonitis. South Med J 95:1158\u20131162","journal-title":"South Med J"},{"key":"4479_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1023\/a:1005437005811","volume":"45","author":"MG Alexandrakis","year":"2000","unstructured":"Alexandrakis MG, Moschandrea JA, Koulocheri SA, Kouroumalis E, Eliopoulos GD (2000) Discrimination between malignant and nonmalignant ascites using serum and ascitic fluid proteins in a multivariate analysis model. Dig Dis Sci 45:500\u2013508. https:\/\/doi.org\/10.1023\/a:1005437005811","journal-title":"Dig Dis Sci"},{"key":"4479_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/1744-9987.13541","volume":"24","author":"H Nakamura","year":"2020","unstructured":"Nakamura H, Hanafusa N, Kitamura K, Nakamura H, Sekihara H, Shimizu K, Anayama M, Makino Y, Tamura K, Nagasawa M (2020) Biochemical evaluation of processed ascites in patients undergoing cell-free and concentrated ascites reinfusion therapy. Ther Apher Dial 24:516\u2013523. https:\/\/doi.org\/10.1111\/1744-9987.13541","journal-title":"Ther Apher Dial"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04479-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04479-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04479-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T17:05:20Z","timestamp":1665594320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04479-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4479"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04479-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Committee of the University of Tsukuba Hospital (Tsukuba, Japan).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}